These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

192 related articles for article (PubMed ID: 15679923)

  • 1. The immunotherapy of Alzheimer's disease.
    Weksler ME
    Immun Ageing; 2004 Nov; 1(1):2. PubMed ID: 15679923
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Amyloid beta peptide immunotherapy in Alzheimer disease.
    Delrieu J; Ousset PJ; Voisin T; Vellas B
    Rev Neurol (Paris); 2014 Dec; 170(12):739-48. PubMed ID: 25459121
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Novel approaches for immunotherapeutic intervention in Alzheimer's disease.
    Vasilevko V; Cribbs DH
    Neurochem Int; 2006 Jul; 49(2):113-26. PubMed ID: 16765487
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Persistent neuropathological effects 14 years following amyloid-β immunization in Alzheimer's disease.
    Nicoll JAR; Buckland GR; Harrison CH; Page A; Harris S; Love S; Neal JW; Holmes C; Boche D
    Brain; 2019 Jul; 142(7):2113-2126. PubMed ID: 31157360
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Developing novel immunogens for a safe and effective Alzheimer's disease vaccine.
    Lemere CA
    Prog Brain Res; 2009; 175():83-93. PubMed ID: 19660650
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Anti-amyloid-beta immunotherapy in Alzheimer's disease: relevance of transgenic mouse studies to clinical trials.
    Wilcock DM; Colton CA
    J Alzheimers Dis; 2008 Dec; 15(4):555-69. PubMed ID: 19096156
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Lack of P-glycoprotein Results in Impairment of Removal of Beta-Amyloid and Increased Intraparenchymal Cerebral Amyloid Angiopathy after Active Immunization in a Transgenic Mouse Model of Alzheimer's Disease.
    Bruckmann S; Brenn A; Grube M; Niedrig K; Holtfreter S; von Bohlen und Halbach O; Groschup M; Keller M; Vogelgesang S
    Curr Alzheimer Res; 2017; 14(6):656-667. PubMed ID: 27915995
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Beneficial effect of human anti-amyloid-beta active immunization on neurite morphology and tau pathology.
    Serrano-Pozo A; William CM; Ferrer I; Uro-Coste E; Delisle MB; Maurage CA; Hock C; Nitsch RM; Masliah E; Growdon JH; Frosch MP; Hyman BT
    Brain; 2010 May; 133(Pt 5):1312-27. PubMed ID: 20360050
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Peripherally administered sera antibodies recognizing amyloid-β oligomers mitigate Alzheimer's disease-like pathology and cognitive decline in aged 3× Tg-AD mice.
    Wang HC; Yu YZ; Liu S; Zhao M; Xu Q
    Vaccine; 2016 Apr; 34(15):1758-66. PubMed ID: 26945100
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Immunotherapy for Alzheimer's disease: from anti-β-amyloid to tau-based immunization strategies.
    Panza F; Frisardi V; Solfrizzi V; Imbimbo BP; Logroscino G; Santamato A; Greco A; Seripa D; Pilotto A
    Immunotherapy; 2012 Feb; 4(2):213-38. PubMed ID: 22339463
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Inflammatory components in human Alzheimer's disease and after active amyloid-β42 immunization.
    Zotova E; Bharambe V; Cheaveau M; Morgan W; Holmes C; Harris S; Neal JW; Love S; Nicoll JA; Boche D
    Brain; 2013 Sep; 136(Pt 9):2677-96. PubMed ID: 23943781
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Immunological approaches for amyloid-beta clearance toward treatment for Alzheimer's disease.
    Solomon B
    Rejuvenation Res; 2008 Apr; 11(2):349-57. PubMed ID: 18341423
    [TBL] [Abstract][Full Text] [Related]  

  • 13. 'Clinical trials in Alzheimer's disease': immunotherapy approaches.
    Delrieu J; Ousset PJ; Caillaud C; Vellas B
    J Neurochem; 2012 Jan; 120 Suppl 1():186-193. PubMed ID: 21883222
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Developing injectable immunoglobulins to treat cognitive impairment in Alzheimer's disease.
    Steinitz M
    Expert Opin Biol Ther; 2008 May; 8(5):633-42. PubMed ID: 18407766
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Immunotherapy for Alzheimer's disease.
    Morgan D
    J Alzheimers Dis; 2006; 9(3 Suppl):425-32. PubMed ID: 16914881
    [TBL] [Abstract][Full Text] [Related]  

  • 16. An attenuated immune response is sufficient to enhance cognition in an Alzheimer's disease mouse model immunized with amyloid-beta derivatives.
    Sigurdsson EM; Knudsen E; Asuni A; Fitzer-Attas C; Sage D; Quartermain D; Goni F; Frangione B; Wisniewski T
    J Neurosci; 2004 Jul; 24(28):6277-82. PubMed ID: 15254082
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Antibody responses, amyloid-beta peptide remnants and clinical effects of AN-1792 immunization in patients with AD in an interrupted trial.
    Kokjohn TA; Roher AE
    CNS Neurol Disord Drug Targets; 2009 Apr; 8(2):88-97. PubMed ID: 19355930
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Amyloid-beta immunotherapy for Alzheimer's disease.
    Fu HJ; Liu B; Frost JL; Lemere CA
    CNS Neurol Disord Drug Targets; 2010 Apr; 9(2):197-206. PubMed ID: 20205640
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Beta-amyloidbased immunotherapy as a treatment of Alzheimers disease.
    Solomon B
    Drugs Today (Barc); 2007 May; 43(5):333-42. PubMed ID: 17724499
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The immune system, amyloid-beta peptide, and Alzheimer's disease.
    Weksler ME; Gouras G; Relkin NR; Szabo P
    Immunol Rev; 2005 Jun; 205():244-56. PubMed ID: 15882358
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.